If you have been reading about tesamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
=== Amateur career === Casey made her amateur debut in 2012, losing a split decision to future UFC Strawweight Emily Kagan. Casey then went on a four fight win streak, earning three wins by armbar and capturing the Tuff-N-Uff Flyweight title in the process and defending it once.
== History == 4-AcO-DMT and several other esters of psilocin were patented on January 16, 1963, by Sandoz via Albert Hofmann and Franz Troxler. The drug's chemical synthesis was improved by David E. Nichols and colleagues in 1999 and it was suggested as a more economical and accessible alternative to psilocybin for use in scientific research. 4-AcO-DMT was first detected as a designer drug in Europe in 2009. It became increasingly prevalent as a recreational drug in the 2010s and has been the most commonly used novel tryptamine. In the 2020s, 4-AcO-DMT became widely encountered in the form of mushroom edibles in the United States as an alternative to psilocybin and psilocybin-containing mushrooms.
Type Ia: thin; lax when the elbow is extended and becomes taut when the elbow is flexed. Type Ib: thick; taut even when the elbow is not fully flexed (90°–120°). Under both definitions, Osborne's ligament forms the roof of the cubital tunnel, an opening between the muscles through which the ulnar nerve passes.
=== Neurotoxicity === Mephedrone has been found to be a monoaminergic neurotoxin in animals and induces serotonergic neurotoxicity. Although some studies in animal models reported no damage to dopamine nerve endings in the striatum and no significant changes in brain monoamine levels, some others suggested a rapid reduction in serotonin transporter (SERT) and dopamine transporter (DAT) function. Persistent serotonergic deficits were observed after binge-like treatment in a warm environment and in both serotonergic and dopaminergic nerve endings at high ambient temperature. Oxidative stress cytotoxicity and an increase in frontal cortex lipid peroxidation were also reported. Although mephedrone has been found to be a monoaminergic neurotoxin, in one study, moderate doses of MDMA produced serotonergic neurotoxicity in rodents whereas mephedrone and methylone did not do so, suggesting that cathinones like mephedrone may be less neurotoxic than their corresponding amphetamine counterparts like MDMA.
Sources: en.wikipedia.org
The catalytic hydrogenation of (S)-1-N-Cbz-prolinamide [34079-31-7] (1) gives L-Prolinamide [7531-52-4] (2). This is condensed with Z-His-NHNH2 [49706-31-2] (3) in the presence of nitrous acid to give Benzyloxycarbonyl-L-histidyl-L-prolineamide, PC13229382 (4). The protecting group is hydrolyzed in acid to give His-pro-amide [33605-69-5] (5). This is finally condensed with (3R,6R)-6-Methyl-5-oxothiomorpholine-3-carboxylic acid, PC99645792 (6) in the presence of by of 1-hydroxybenzotriazole and dicyclohexylcarbodiimide, completing the synthesis of Montirelin (7).
== Notable people == Pope Pius I is believed to have been born at Aquileia during the late first century. Saint Chrysogonus was martyred here in the beginning of the fourth century. Licia Kokocinski - Australian politician
Masson's trichrome is (as the name implies) a three-colour staining protocol. The recipe has evolved from Masson's original technique for different specific applications, but all are well-suited to distinguish cells from surrounding connective tissue. Most recipes produce red keratin and muscle fibers, blue or green staining of collagen and bone, light red or pink staining of cytoplasm, and black cell nuclei.
== Selected publications == Dendrosome: Dendrosomes: a novel family of vehicles for transfection and therapy. Journal of Chemical Technology & Biotechnology. Volume 75 Issue 10, Pages 919 - 922 (2000) Dendrosomes as novel gene porters-III. Journal of Chemical Technology & Biotechnology Volume 83 Issue 6, Pages 912 - 920 (2008) Structural biology: Functional and structural characterization of a novel member of the natriuretic family of peptides from the venom of Pseudocerastes persicus. FEBS Letters Volume 557 Issue 1-3, Pages 104-108 (2004) Solution structure of long neurotoxin NTX-1 from the venom of Naja naja oxiana by 2D-NMR spectroscopy. European Journal of Biochemistry Volume 271 Issue 23-24 Pages 4950-4957 (2004) Biomaterials: Synthesis and thermal behavior of triblock copolymers from L-lactide and ethylene glycol with long center PEG block. Journal of Applied Polymer Science Volume 68 Issue 12 Pages 1949-1954 (1998) Synthesis and characterization of novel biodegradable triblock copolymers from L-lactide, glycolide, and PPG. Journal of Applied Polymer Science Volume 73 Issue 5 Pages 633-637 (1999) Synthesis and characterization of ABA triblock and novel multiblock copolymers from ethylene glycol, L-lactide, and epsilon-caprolactone. Journal of Applied Polymer Science Volume 83 Issue 10 Pages 2072-2081 (2002) Mass preparation and characterization of alginate microspheres. Process Biochemistry Volume 35 Issue 9 Pages 885-888 (2000) Membranes: A simple method for preparation of immuno-magnetic liposomes.
== Description == The species grows to be about 50 mm, or about 2 inches. This slug has been treated as a model organism and used in studies into classical conditioning, memory consolidation and associative learning, the structure of neural circuits and neural physiology. It has also been used to investigate ultrastructure and anatomy, larval and reproductive ecology, behavioral ecology and pharmacology and toxicology including studies into Beta thymosins. Unfortunately these studies did not differentiate between the three species of Hermissenda.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.